parvofighter
Senior Member
- Messages
- 440
- Location
- Canada
BMJ and XMRV Unplugged
PART 1
Much has been made of the well-characterized or well-defined patient cohorts (http://www.bmj.com/cgi/content/abstract/340/feb25_1/c1018) of the failed XMRV-in-ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) replication attempts. Well characterized somberly implies that the patients studied were robustly and meaningfully comparable to those in the landmark Science XMRV study. Namely: Canadian/Fukuda Criteria Chronic Fatigue Syndrome patients with severe disability, reproducible immune abnormalities, cognitive deficits, prolonged, disabling fatigue, low V02 max, and multiple longitudinal measurements of clinical and laboratory abnormalities (http://www.sciencemag.org/cgi/content/full/1179052/DC1 ).
Well-characterized carries an aura of respectability defying readers to challenge the issue of cohort selection in XMRV research. And it has been abundantly used in the checkered history of Chronic Fatigue Syndrome research. The latest well-characterized XMRV study in Chronic Fatigue Syndrome was ushered into the expectant scientific community by the esteemed British Medical Journal. In her Editors Choice letter (http://www.bmj.com/cgi/content/full...FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT ) accompanying the latest XMRV retroviral study by psychiatrists (Van Kuppeveld et al), Fiona Godlee empathetically waxed poetic on the roller coaster of emotions ME/CFS patients had endured since the BMJs publication of the latest rebuttal of XMRV/CFS research:
With a funereal tone, Godlee cited the somber news that, claims of association between retroviruses and diseases often fail to withstand the test of time (doi:10.1136/bmj.c1099). AIDS patients around the world bowed their heads in silence as the coffin began to close on XMRVs association with ME/CFS.
Godlee went on to provide a thrilling and compelling rationale for the BMJs publication of the latest XMRV research:
Godlee gamely heralded a new era of scientific excellence for Chronic Fatigue Syndrome and XMRV, entitling her missive with the serious invocation: Lets Proceed with Caution. Godlee wisely enlisted the help of experts: Cathie Sudlow stepped up to the plate to help her navigate the minefields of credible scientific enquiry:
Godlee may be handicapped when it comes to irony, and Sudlow, when it comes to reading Sciences Supporting Online Materials (www.sciencemag.org/cgi/content/full/1179052/DC1 ) but they are a force to be reckoned with when it comes to promoting quality scientific research. Godley closed her tome on XMRV and ME/CFS with a flourish:
Despite her evident talents as a BMJ editor, Godlee is subtly handicapped when it comes to her sense of irony. But this doesnt deter her zealous scientific pursuits. Godlees, and indeed the BMJs enthusiasm for quality medical research is iron-clad particularly when it is associated with a retrovirus believed to cause devastating neuro-immune disease and cancer - and this we enthusiastically applaud.
In Part 2, lets next explore the wonders of Van Kuppeveld et als BMJ XMRV work, and the source of their highly credible patient cohort.
PART 1
Much has been made of the well-characterized or well-defined patient cohorts (http://www.bmj.com/cgi/content/abstract/340/feb25_1/c1018) of the failed XMRV-in-ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) replication attempts. Well characterized somberly implies that the patients studied were robustly and meaningfully comparable to those in the landmark Science XMRV study. Namely: Canadian/Fukuda Criteria Chronic Fatigue Syndrome patients with severe disability, reproducible immune abnormalities, cognitive deficits, prolonged, disabling fatigue, low V02 max, and multiple longitudinal measurements of clinical and laboratory abnormalities (http://www.sciencemag.org/cgi/content/full/1179052/DC1 ).
Well-characterized carries an aura of respectability defying readers to challenge the issue of cohort selection in XMRV research. And it has been abundantly used in the checkered history of Chronic Fatigue Syndrome research. The latest well-characterized XMRV study in Chronic Fatigue Syndrome was ushered into the expectant scientific community by the esteemed British Medical Journal. In her Editors Choice letter (http://www.bmj.com/cgi/content/full...FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT ) accompanying the latest XMRV retroviral study by psychiatrists (Van Kuppeveld et al), Fiona Godlee empathetically waxed poetic on the roller coaster of emotions ME/CFS patients had endured since the BMJs publication of the latest rebuttal of XMRV/CFS research:
Meanwhile, and sadly for those whose hopes had been raised, the (Science) study has been refuted by three further case-control studies, one of them in the BMJ (doi:10.1136/bmj.c1018).
Godlee went on to provide a thrilling and compelling rationale for the BMJs publication of the latest XMRV research:
The paper by Van Kuppeveld and colleagues is an unusual paper for the BMJ to publish. As our research highlights page explains, we would usually reject a small case-control study examining the prevalence of a virus in 20 year old blood samples. Instead we fast tracked it. We did this because its about an important and debilitating syndrome thats often seen by generalists and because we felt it added to an important and highly controversial debate. We and our reviewers also thought it was well done.
As an epidemiologist, Cathie Sudlows initial response was skeptical, quickly confirmed when she saw that the paper lacked basic methodological information. "Where were the details of the characteristics and selection procedures for the cases and controls, or of blinding of researchers to the case-control status of the samples? Where was the discussion of the potential role of bias and confounding?".
So yes, lets have more research into chronic fatigue syndrome,
but lets make sure its good enough research.
but lets make sure its good enough research.
In Part 2, lets next explore the wonders of Van Kuppeveld et als BMJ XMRV work, and the source of their highly credible patient cohort.